In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies.
about
RNA vaccines in cancer treatmentProduction and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas.RNA-Based Vaccines in Cancer ImmunotherapyImmunity to Pathogens Taught by Specialized Human Dendritic Cell SubsetsImmunotherapy in gastric cancerAn mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn PigsIntradermal electroporation of naked replicon RNA elicits strong immune responsesSelf-replicating Replicon-RNA Delivery to Dendritic Cells by Chitosan-nanoparticles for Translation In Vitro and In VivoAdjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate responseIntranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunitymRNA vaccine delivery using lipid nanoparticles.BALB/c mice show impaired hepatic tolerogenic response following AAV gene transfer to the liver.RNA-transfected dendritic cells in cancer immunotherapy.Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene.Characterization of the ribonuclease activity on the skin surface.Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.A cationic nanoemulsion for the delivery of next-generation RNA vaccines.Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa studyLong-term storage of DNA-free RNA for use in vaccine studiesStabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8.Multifunctional triblock copolymers for intracellular messenger RNA deliveryBiomaterials for mRNA delivery.Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy.Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines.Developing mRNA-vaccine technologies.Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals.Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy.Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single doseRNA-based immunotherapy of cancer: role and therapeutic implications of dendritic cells.A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines.Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy.mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugsMessenger RNA (mRNA) nanoparticle tumour vaccinationLuciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity.From the RNA world to the clinic.CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.Viral and Synthetic RNA Vector Technologies and Applications.RNA Vaccination Therapy: Advances in an Emerging Field.
P2860
Q21296852-133C5A90-DEC4-436A-ABF3-B129F468A796Q24814838-F1964DCC-4AC8-4A0C-A01F-3B53BDC0DBB7Q26776028-E6844318-4E58-4FC8-AEC6-9CDDE5BDB4BFQ26777195-2EAA01B8-F095-48AA-95FF-336D76251BF2Q27010472-BC3867AE-903B-4D67-8158-3551F62FA1B6Q27303650-8FB5EEE0-2C67-438B-86AB-3F18BA38E5D2Q27310340-69F1B0AD-9355-425D-A156-FDA96D50F91BQ28654968-C298464C-61A0-45F7-8CDC-243BB3151D3FQ30397031-8268A437-FA41-49A8-824C-71D8FB5C2601Q33708572-2AA002E9-34DD-4A21-A652-0D5E4B2B6D1DQ33711685-1AF9DAFD-C047-4748-B3C9-82EE8A31E626Q33822204-F6DAED2B-A04A-459F-A230-9A0F62235CB2Q34078072-B68F2D36-A6E9-4781-B206-4D5055860CF7Q34326532-206F4408-3E58-40D5-9C50-58D2D28B4A0DQ34880734-B70E6D43-F6CE-4D08-B4CD-B122229444E0Q34994511-7CC504B2-928F-459A-9040-E95011B5609FQ35018021-0CAF6723-0DE8-4F2D-A2AC-6768431E6DE5Q35600305-B769A374-8306-4EB0-8D17-6C1033EEF735Q35746834-ED778318-8461-40FA-8D1B-9E99A3CBD26AQ35920469-384815AA-85C1-4B01-AA6F-D23FB5FECCE7Q35963017-A206ABBD-3000-4F33-A53E-F078229312FAQ36140780-89BEA8D1-19EC-4A08-988D-65139C8244E6Q36271488-0AC8F93D-8454-4A83-AB3D-248C9161299EQ36417403-C2ABB8E4-79E7-40E5-8D21-A998D8FD8755Q36512540-4EEB293C-1631-4470-B84F-3AEC2A639D8BQ36684597-AD7DBE0A-ADF3-47C4-90A3-A84EB6FDB8CFQ36757051-4C46448C-2C2C-4BE0-B879-CF0E4A480D7CQ37012691-272B01A8-C128-47B1-AFF2-C555CEAD9FF1Q37126611-7D335FED-AEF5-4650-8654-F6EB2EF80CECQ37357300-61CF73C3-F8E9-4CE7-8795-370F7D87F8B0Q37530550-3488120C-EA0A-48AC-8D13-0C179C63B0D0Q37559326-0EA12F59-3D71-4D6B-BE34-97071C2E7381Q38071900-F719638C-7116-4E53-9544-DF1D13254298Q38206520-A815970F-76F9-4704-976F-B78A5CCDB2A2Q38218147-4B6E52E6-3EE6-4C35-A255-498AB74F6845Q38779887-DF745188-8BF9-4946-9E9A-728A885190A0Q38851919-CA97E41F-5B06-457E-9B1E-20D66C0C631BQ38853141-5F4C2129-E2F6-45CB-97DB-7F784DB34802Q38885624-DB250EFD-422E-477E-899C-F27AE9F3A791Q38891036-E97A129D-2B1A-4A35-BCE4-946F841C96E2
P2860
In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
In vivo application of RNA lea ...... T lymphocytes and antibodies.
@ast
In vivo application of RNA lea ...... T lymphocytes and antibodies.
@en
type
label
In vivo application of RNA lea ...... T lymphocytes and antibodies.
@ast
In vivo application of RNA lea ...... T lymphocytes and antibodies.
@en
prefLabel
In vivo application of RNA lea ...... T lymphocytes and antibodies.
@ast
In vivo application of RNA lea ...... T lymphocytes and antibodies.
@en
P2093
P1476
In vivo application of RNA lea ...... T lymphocytes and antibodies.
@en
P2093
P356
10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.3.CO;2-R
P407
P577
2000-01-01T00:00:00Z